Pulsed-Field Ablation Demonstrates Superior Efficacy and Safety Profile in Landmark Sham-Controlled Trial and Real-World Registry
核心洞察
The first sham-controlled trial of pulsed-field ablation (搜索) (PFA-SHAM) demonstrated 94% freedom from atrial arrhythmias at 6 months compared to 17% with sham procedure, establishing definitive efficacy beyond placebo effects.
MANIFEST-US registry of 41,968 patients showed exceptionally low complication rates with PFA, including 0.63% major adverse events and no cases of atrioesophageal fistula or persistent phrenic nerve injury.
PFA has largely displaced thermal ablation modalities in clinical practice due to its tissue specificity and improved safety profile, expanding treatment options for higher-risk atrial fibrillation (搜索) patients.
Pulsed-field ablation (搜索) (PFA) has achieved a significant milestone with the completion of the first sham-controlled trial demonstrating its efficacy for atrial fibrillation (搜索) (AF), while a large real-world registry confirms its exceptional safety profile. The findings, presented at the American Heart Association 2025 Scientific Sessions, provide definitive evidence supporting PFA's rapid adoption in clinical practice.
Sham-Controlled Trial Establishes Definitive Efficacy
The PFA-SHAM trial, conducted by Vivek Reddy, MD, at the Icahn School of Medicine at Mount Sinai, represents a crucial advancement in establishing PFA's therapeutic benefit beyond placebo effects. The investigator-initiated trial included 60 patients with highly symptomatic paroxysmal or persistent AF, defined as an AF Effect on Quality of Life Questionnaire (AFEQT) score of 50 or less.
Patients were randomized to receive PFA using the Farapulse (搜索) system (Boston Scientific) under deep sedation or a sham procedure consisting of extended deep sedation. The trial achieved remarkable results for both coprimary endpoints. Freedom from atrial arrhythmias at 6 months was achieved in 94% of PFA patients compared to 17% in the sham arm, with a posterior probability of superiority greater than 99.99%.
Quality of life improvements were equally impressive, with AFEQT scores improving by approximately 40 points with PFA versus 10 points with sham control. The posterior probability of superiority again exceeded 99.99%. PFA also demonstrated significant benefits in reducing AF burden and improving psychological distress as measured by the Hospital Anxiety and Depression Scale.
"It provides strong evidence of efficacy of the active treatment and evidence against it just being a placebo effect," noted Daniel Morin, MD, from the University of California, San Francisco, who discussed the trials. "And it treats both the doctor and the patient."
Real-World Safety Data from 41,968 Patients
The MANIFEST-US registry, reported by Mohit Turagam, MD, provided comprehensive safety data from real-world use of the Farapulse (搜索) system following its approval in early 2024. The retrospective study included 41,968 patients (mean age 68.3 years; 43.9% women) treated at 102 US centers between February 2024 and June 2025.
Major adverse events occurred in only 0.63% of patients, with specific complications including vascular complications requiring intervention (0.18%), pericardial tamponade (搜索) (0.16%), stroke (搜索) within 7 days (0.1%), and coronary artery spasm (搜索) (0.1%). Notably, no cases of atrioesophageal fistula, pulmonary vein stenosis, or persistent phrenic nerve injury were observed.
Minor complications occurred in 2.1% of patients, primarily consisting of hematoma (0.69%) and pericarditis (0.52%). The overall 30-day mortality rate was exceptionally low at 0.04%, including eight cases of unexplained sudden death or arrest.
A detailed analysis of 40 coronary vasospasm cases revealed that 75% were proximity-related, most commonly from cavotricuspid isthmus ablation. One-quarter were generalized spasms, with 70% having clinical sequelae including cardiogenic shock and arrhythmias.
Transforming Clinical Practice
PFA has fundamentally altered the landscape of AF ablation, largely displacing thermal modalities including radiofrequency and cryoballoon ablation. Mina Chung, MD, president of the Heart Rhythm Society (搜索), emphasized that PFA's mechanism of action and specificity for myocardial tissue (搜索) carries lower risks of damage to surrounding structures.
"We've seen a lot of encouraging results for its efficacy, improving durability and, especially, safety," Chung stated. "I think that's where the most important aspect has come in and has expanded our scope of application to patients that may have been excluded due to higher risk."
The technology's safety profile has enabled treatment of higher-risk patients previously excluded from ablation procedures, preventing complications such as atrioesophageal fistula, pulmonary vein stenosis, and phrenic nerve paralysis that can occur with thermal ablation methods.
Regulatory and Clinical Developments
The field experienced a temporary setback early in 2025 when use of the Varipulse (搜索) PFA system (Johnson & Johnson MedTech (搜索)) was halted for approximately one month following four neurovascular events. Company investigation indicated that risk "may increase if a high number of ablations, the stacking of ablations, and/or ablations outside of the pulmonary veins (搜索) are delivered."
Despite this temporary pause, the technology continues to advance with new catheter designs, including systems capable of delivering both pulsed-field and radiofrequency energy. Emerging evidence suggests potential applications beyond AF, including ventricular tachycardia (搜索) treatment.
Future Directions and Data Collection
The Heart Rhythm Society (搜索) announced plans to develop a comprehensive PFA data collection platform incorporating advanced automation, artificial intelligence, and electronic health record integration. The platform aims to track real-world procedural results, complications, and patient outcomes with reduced burden on participating sites.
"This could be transformative when it comes to tracking the results of PFA, including complications and patient outcomes," Chung noted. The initiative plans to launch pilot sites in early 2026 with full implementation by 2027.
The field also anticipates continued improvements in catheter technology, including better integration of high-density electroanatomic mapping capabilities. As Chung observed, "This is an exciting time for electrophysiology."
Expanding Access Through Ambulatory Centers
The US Centers for Medicare & Medicaid Services delivered significant news in November by adding cardiac catheter ablation to covered procedures when performed in ambulatory surgical centers (ASCs). This development, outlined in the 2026 Hospital Outpatient Prospective Payment System final rule, promises to expand patient access to PFA procedures.
However, Chung emphasized the importance of maintaining appropriate patient selection and clinical standards. "We need to assure that appropriate patients are selected for doing these procedures in ASCs; that good clinical practice and standards are upheld, including standards for the facility, physician, and staffing requirements."